Credo Technology Group Holding and 2 insider selections for significant growth

With the U.S. stock market reaching new heights, particularly the Dow and S&P 500 hitting record levels, investors are keen on finding growth opportunities in the current economic climate. Companies that have significant insider ownership are starting to draw more attention, mostly because this often indicates confidence from those who know the business best—something that could resonate well with the prevailing market optimism.

Now, let’s highlight a few notable companies from the recent findings.

Simply Wall Street Growth Assessment: ★★★★★

Overview: Credo Technology Group Holding Ltd, valued at about $27.17 billion, offers high-speed connectivity solutions for optical and electrical Ethernet as well as PCIe applications across the U.S., Taiwan, mainland China, Hong Kong, and beyond.

Operation: The majority of the company’s revenue comes from its semiconductor sector, which reported $796.13 million.

Insider Ownership: 10.1%

Revenue Growth Forecast: 27.2% per year

Credo has shown impressive financials, evidenced by its revenue increase and return to profitability in the second quarter of 2026, posting a net profit of $82.64 million. The firm’s innovative offerings, such as the Weaver memory fan-out gearbox and ZeroFlap optical transceiver, have strengthened its footing in the AI infrastructure sphere. Even with some stock price volatility and notable insider sales recently, its projected sales and earnings growth exceed market benchmarks.

Simply Wall Street Growth Assessment: ★★★★★☆

Overview: Krystal Biotech, Inc., a commercial-stage biotech firm, has a market cap of about $7.58 billion and is dedicated to developing genetic medicines targeting severe unmet medical needs in the U.S.

Operation: The company’s revenue largely comes from its genetic medicine segment, contributing $373.16 million.

Insider Ownership: 10.3%

Revenue Growth Forecast: 23.9% per year

Krystal Biotech has experienced rapid growth, with revenues soaring by 279.8% over the last year and an annual growth forecast of 26.74%. Positive outcomes from the Phase 1 study of KB407 for cystic fibrosis bolster its innovative standing. While future return on equity predictions might seem modest, the ongoing advancements in genetic medicine, including the FDA’s recognition of its technology platform, enhance its prospects in the healthcare space.

Simply Wall Street Growth Assessment: ★★★★★☆

Overview: Hyatt Hotels Corporation operates in both the U.S. and internationally, boasting a market capitalization of roughly $15.97 billion.

Operation: The company generates revenue from various segments, including distribution ($974 million), owned and leased properties ($1.24 billion), and management and franchising ($1.19 billion).

Insider Ownership: 10.8%

Revenue Growth Forecast: 20.1% per year

Hyatt has seen considerable growth, marked by recent expansions in locations like China and Puerto Rico. Its revenue surged to $1.79 billion in Q3 2025, up from a previous net loss of $49 million. Looking ahead, the company forecasts strong annual earnings growth, expecting to outperform the market with a robust revenue increase of 20.1% each year. Insider transactions recently show a trend of more shares being purchased than sold, suggesting confidence in the company’s strategic direction amidst ongoing global expansion.